YANG, SANG-IN,杨尙仁,楊尙仁,WOO, JUNG-WON,禹晶媛,YANG, SE HWAN,梁世涣,SUNG, YOUNG CHUL,成永喆,PARK, DOO HONG,朴斗鸿,朴斗鴻,KIM, MIN WOO,金民雨
申请号：
TW105100659
公开号：
TW201636042A
申请日:
2016.01.08
申请国别(地区):
TW
年份:
2016
代理人:
摘要：
The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.本發明係涉及一種使用持續釋放EPO之製劑治療貧血之方法，更具體地，一種將包括EPO及免疫球蛋白雜合Fc的融合多肽施予貧血患者，確保安全、持續釋放及最佳化有效用量及用法而治療貧血患者的方法。施予融合多肽的方法採用適當的用量及用法，相較於現有EPO產品，該方法不但顯示具有優異持續釋放特性，而且將由於快速增加血紅素值而可能發生的心血管副作用最小化，其係有效之貧血治療。
